TY - JOUR T1 - Dupilumab provides favourable long鈥恡erm safety and efficacy in children aged 鈮� 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open鈥恖abel phase IIa study and subsequent phase III open鈥恖abel extension study JO - British Journal of Dermatology PY - 2020/09/24 AU - Cork MJ AU - Tha莽i D AU - Eichenfield LF AU - Arkwright PD AU - Sun X AU - Chen Z AU - Akinlade B AU - Boklage S AU - Guillemin I AU - Kosloski MP AU - Kamal MA et al ED - DO - DOI: 10.1111/bjd.19460 PB - Wiley Y2 - 2025/04/09 ER -